{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T21:16:13Z","timestamp":1793308573310,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Homi Bhabha Cancer Hospital (HBCH) Varanasi"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-97923-2","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T07:29:13Z","timestamp":1748417353000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Real-world data on trastuzumab emtansine (TDM1) efficacy and safety: Results of a single-centre retrospective study of HER2-positive metastatic breast cancer patients"],"prefix":"10.1038","volume":"15","author":[{"given":"Anuj","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bipinesh","family":"Sansar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bal Krishna","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aqusa","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arpita","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Upadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachariah","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashikant","family":"Patne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayank","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreya","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satyendra Narayan","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lincoln","family":"Pujari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashanth","family":"Giridhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankita Rungta","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Suresh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somnath","family":"Dey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunal Ranjan","family":"Vinayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankita","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhil","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"key":"97923_CR1","doi-asserted-by":"publisher","first-page":"e1027","DOI":"10.1016\/S2214-109X(20)30215-1","volume":"8","author":"E Heer","year":"2020","unstructured":"Heer, E. et al. Global burden and trends in premenopausal and postmenopausal breast cancer: A population-based study. Lancet Glob. Health 8, e1027\u2013e1037 (2020).","journal-title":"Lancet Glob. Health"},{"key":"97923_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"issue":"20","key":"97923_CR3","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff, A. C. et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update. J. Clin. Oncol. 36(20), 2105\u20132122 (2018).","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"97923_CR4","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1634\/theoncologist.2008-0230","volume":"14","author":"JS Ross","year":"2009","unstructured":"Ross, J. S. et al. The HER-2 receptor and breast cancer: Ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist. 14(4), 320\u2013368 (2009).","journal-title":"Oncologist."},{"issue":"2","key":"97923_CR5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa1113216","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga, J. et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 366(2), 109\u2013119 (2012).","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"97923_CR6","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma, S. et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 367(19), 1783\u20131791 (2012).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"97923_CR7","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/annonc\/mdu486","volume":"26","author":"IE Krop","year":"2015","unstructured":"Krop, I. E. et al. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: A retrospective, exploratory analysis in EMILIA. Ann. Oncol. 26(1), 113\u2013119 (2015).","journal-title":"Ann. Oncol."},{"issue":"7","key":"97923_CR8","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S1470-2045(14)70178-0","volume":"15","author":"IE Krop","year":"2014","unstructured":"Krop, I. E. et al. Trastuzumab emtansine versus treatment of physician\u2019s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): A randomized, open-label, phase 3 trial. Lancet Oncol. 15(7), 689\u2013699 (2014).","journal-title":"Lancet Oncol."},{"issue":"5","key":"97923_CR9","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1002\/cncr.28465","volume":"120","author":"M Welslau","year":"2014","unstructured":"Welslau, M. et al. Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer. Cancer 120(5), 642\u2013651 (2014).","journal-title":"Cancer"},{"issue":"7","key":"97923_CR10","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz, G. et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N. Engl. J. Med. 380(7), 617\u2013628 (2019).","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"97923_CR11","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s10549-010-1090-x","volume":"128","author":"TT Junttila","year":"2011","unstructured":"Junttila, T. T., Li, G., Parsons, K., Phillips, G. L. & Sliwkowski, M. X. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib-insensitive breast cancer. Breast Cancer Res. Treat. 128(2), 347\u2013356 (2011).","journal-title":"Breast Cancer Res. Treat."},{"issue":"6","key":"97923_CR12","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1158\/0008-5472.CAN-09-3546","volume":"70","author":"YV Kovtun","year":"2010","unstructured":"Kovtun, Y. V. et al. Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res. 70(6), 2528\u20132537 (2010).","journal-title":"Cancer Res."},{"issue":"17","key":"97923_CR13","doi-asserted-by":"publisher","first-page":"4436","DOI":"10.1158\/1078-0432.CCR-14-0012","volume":"20","author":"L Amiri-Kordestani","year":"2014","unstructured":"Amiri-Kordestani, L. et al. FDA approval: Ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin. Cancer Res. 20(17), 4436\u20134441 (2014).","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"97923_CR14","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S1470-2045(17)30313-3","volume":"18","author":"IE Krop","year":"2017","unstructured":"Krop, I. E. et al. Trastuzumab emtansine versus treatment of physician\u2019s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): Final overall survival results from a randomized open-label phase 3 trial. Lancet Oncol. 18(6), 743\u2013754 (2017).","journal-title":"Lancet Oncol."},{"issue":"5","key":"97923_CR15","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/j.1524-4733.2007.00186.x","volume":"10","author":"LP Garrison","year":"2007","unstructured":"Garrison, L. P., Neumann, P. J., Erickson, P., Marshall, D. & Mullins, C. D. Using real-world data for coverage and payment decisions: The ISPOR real-world data task force report. Value Health. 10(5), 326\u2013335 (2007).","journal-title":"Value Health."},{"issue":"10371","key":"97923_CR16","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","volume":"401","author":"SA Hurvitz","year":"2023","unstructured":"Hurvitz, S. A. et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet 401(10371), 105\u2013117 (2023).","journal-title":"Lancet"},{"key":"97923_CR17","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.breast.2019.05.011","volume":"46","author":"AM Hopkins","year":"2019","unstructured":"Hopkins, A. M., Rowland, A., Logan, J. M. & Sorich, M. J. Primary predictors of survival outcomes for HER2-positive advanced breast cancer patients initiating ado-trastuzumab emtansine. Breast 46, 90\u201394 (2019).","journal-title":"Breast"},{"issue":"7","key":"97923_CR18","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s10585-015-9740-3","volume":"32","author":"R Bartsch","year":"2015","unstructured":"Bartsch, R. et al. Activity of T-DM1 in HER2-positive breast cancer brain metastases. Clin. Exp. Metastasis. 32(7), 729\u2013737 (2015).","journal-title":"Clin. Exp. Metastasis."},{"issue":"5","key":"97923_CR19","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s11912-019-0802-6","volume":"21","author":"JP Leone","year":"2019","unstructured":"Leone, J. P. & Lin, N. U. Systemic therapy of central nervous system metastases of breast cancer. Curr. Oncol. Rep. 21(5), 49 (2019).","journal-title":"Curr. Oncol. Rep."},{"issue":"6","key":"97923_CR20","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S1470-2045(16)00163-7","volume":"17","author":"L Gianni","year":"2016","unstructured":"Gianni, L. et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): A multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 17(6), 791\u2013800 (2016).","journal-title":"Lancet Oncol."},{"issue":"1","key":"97923_CR21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","volume":"13","author":"L Gianni","year":"2012","unstructured":"Gianni, L. et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 13(1), 25\u201332 (2012).","journal-title":"Lancet Oncol."},{"issue":"(15_suppl)","key":"97923_CR22","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1200\/JCO.2016.34.15_suppl.500","volume":"34","author":"S Hurvitz","year":"2016","unstructured":"Hurvitz, S. et al. Pathologic complete response rates after neoadjuvant trastuzumab emtansine (T-DM1) plus pertuzumab vs. docetaxel plus carboplatin plus trastuzumab plus pertuzumab (TCH+P) treatment in patients with HER2-positive early breast cancer (KRISTINE\/TRIO-021). J. Clin. Oncol. 34((15_suppl)), 500 (2016).","journal-title":"J. Clin. Oncol."},{"issue":"25","key":"97923_CR23","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1200\/JCO.2013.54.4999","volume":"32","author":"V Di\u00e9ras","year":"2014","unstructured":"Di\u00e9ras, V. et al. Trastuzumab emtansine in HER2-positive metastatic breast cancer: An integrated safety analysis. J. Clin. Oncol. 32(25), 2750\u20132757 (2014).","journal-title":"J. Clin. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97923-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97923-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97923-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T07:29:14Z","timestamp":1748417354000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97923-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["97923"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-97923-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,28]]},"assertion":[{"value":"6 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18669"}}